U.S. Department of Health and Human Services
 

 Staff Contacts

 

Programmatic innovative research and technology research questions

Administrative and business management questions​


  • General Inquiries and Kidney, Urologic, and Hematologic Diseases (KUH)

  • Diabetes, Endocrinology, and Metabolic Diseases (DEM)​

  • Digestive Diseases and Nutrition (DDN)

Programs for Current Awardees

Phase IIB Competing Renewal Awards

NIDDK will accept Phase IIB SBIR/STTR Competing Renewal grant applications from NIDDK supported Phase II awardees that propose to continue the process of developing products that ultimately require:

  1. Clinical evaluation
  2. Approval by a Federal regulatory agency
  3. Continuing refinements to durable medical equipment (DME) designs such as cost reduction, testing for safety, durability, and reliability, and meeting or establishing standards
​This renewal grant should allow small businesses to get to a stage where interest and investment by third parties is more likely. Such products include, but are not limited to biological products, devices, drugs, medical implants, etc. related to the mission of the NIDDK. The previously funded Phase II SBIR/STTR grant need not have been submitted in response to a particular solicitation, as long as the research is appropriate to the purpose of this solicitation. Budgets up to $1,000,000 total costs per year and time periods up to 3 years may be requested. Contact NIDDK staff for more information. 

 

NIH Technical Assistance Programs

Two NIH-wide technical assistance programs are available to SBIR/STTR awardees.The NIDDK encourages SBIR/STTR awardees to stay up-to-date on the latest NIH SBIR/STTR updates and make use of NIH Technical Assistance Programs when announced.

Commercialization Assistance Program (CAP)

The NIH SBIR/STTR Commercialization Assistance Program is a specialized technical assistance program for SBIR/STTR Phase II awardees. The CAP is designed to help promising small life science and healthcare companies develop their commercial businesses and transition their SBIR/STTR-developed technologies into the marketplace. It is a 9-month program, consisting of training workshops, individual mentoring and consulting sessions, and public events in which companies present their technologies to the biomedical and biotechnology investment communities, potential strategic partners, and licensees. The program begins each fall.

Niche Assessment Program (NAP)

The NIH SBIR/STTR Niche Assessment Program was created to provide SBIR/STTR Phase I awardees with market analysis and suggest a commercialization strategy that includes tasking, and a schedule for implementation. NIH has contracted with Foresight Science and Technology to perform Technology Niche Analyses (TNA™) for 136 NIH SBIR/STTR Phase I awardees funded in fiscal year 2014. The TNA™ will assess potential uses of the technology and result in a report that addresses the end-user needs, competing technologies and products, the competitive advantage of the technology, key competitors, potential customers and commercialization partners. ​​​​This program was announced in the fall and is available on first come, first served basis.